73746-45-9

Usage

Uses

Used in Pharmaceutical Industry:
2-Methyl-4(5)-iodo-1(H)-imidazole is utilized as a key intermediate in the synthesis of pharmaceuticals, specifically for developing antifungal and antibacterial agents. Its unique structure contributes to the potency and effectiveness of these medications, targeting a range of microbial infections.
Used as a Reagent in Organic Synthesis:
In the realm of organic chemistry, 2-Methyl-4(5)-iodo-1(H)-imidazole serves as a reagent facilitating the synthesis of other organic compounds. Its reactivity and stability make it a valuable component in a variety of chemical reactions, broadening its applications in research and industrial processes.
Used as a Corrosion Inhibitor:
Beyond its pharmaceutical applications, 2-Methyl-4(5)-iodo-1(H)-imidazole also functions as a corrosion inhibitor. It protects materials from the degrading effects of corrosive agents, extending the service life of various industrial equipment and structures.
Used in Material Science and Drug Discovery:
2-METHYL-4(5)-IODO-1(H)-IMIDAZOLE holds potential in material science for the development of new materials, leveraging its chemical properties to enhance material performance. Additionally, it is explored in drug discovery for its possible contribution to the creation of novel therapeutic agents, indicating a promising future in medicinal chemistry.

InChI:InChI=1/C4H5IN2/c1-3-6-2-4(5)7-3/h2H,1H3,(H,6,7)

Upstream product

• 693-98-1 2-methylimidazole 
• 73746-44-8 4,5-diiodo-2-methyl-1H-imidazole 
• 109-72-8 n-butyllithium 

Downstream Products

• 941287-07-6 1-benzyl-4-iodo-2-methyl-1H-imidazole 
• 13739-48-5 2-methyl-4-phenyl-1H-imidazole 
• 157255-72-6 4-iodo-2-methyl-1-triphenylmethylimidazole 
• 102791-92-4 1-(3-methyl-4-nitro-phenyl)-1H-imidazole 
• 111566-79-1 4-Iodo-2-methyl-1-(3-methyl-4-nitrophenyl)imidazole 
• 693-98-1 2-methylimidazole 
• 1334675-68-1 4-iodo-2-methyl-1-phenyl-1H-imidazole 
• 1334675-69-2 1-phenyl-2-methyl-5-iodoimidazole 
• 1167623-56-4 6-(2-methyl-1H-imidazol-4-yl)-N-phenylimidazo[1,2-a]pyridine-2-carboxamide 
• 808773-38-8 4-(3-chloro-phenylethynyl)-2-methyl-1H-imidazole 

Relevant academic research and scientific papers

Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1

Indoleamine 2,3-dioxygenase 1 (IDO1), promoting immune escape of tumors, is a therapeutic target for the cancer immunotherapy. A number of IDO1 inhibitors have been identified, but only limited structural biology studies of IDO1 inhibitors are available t

Pyrrolopyrazine Kinase Inhibitors

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables n, p, q, Q, X, X′ and Y are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

Discovery of MK-5046, a potent, selective bombesin receptor subtype-3 agonist for the treatment of obesity

We report the development and characterization of compound 22 (MK-5046), a potent, selective small molecule agonist of BRS-3 (bombesin receptor subtype-3). In pharmacological testing using diet-induced obese mice, compound 22 caused mechanism-based, dose-

Direct synthesis of pyrroles via a silver-promoted three-component reaction involving unusual imidazole ring opening

A novel silver-promoted three-component reaction toward the synthesis of multifunctionalized pyrroles has been developed. This reaction involves an unusual imidazole ring decomposition, presumably via 1,5-isomerization and subsequent hydrolysis.

Substituted inmidazoles as bombesin receptor subtype-3 modulators

Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.

Synthesis of 4,4'-biimidazoles

The palladium(0) catalysed coupling reaction of 4-iodo-1-triphenylmethylimidazole (7) or its 2-methyl analogue 8 afforded the 4,4'-biimidazoles 9 and 10, respectively. Treatment of these compounds with 60% aqueous trifluoroacetic acid gave 4,4'-biimidazole and 2,2'-dimethyl-4,4'-biimidazole as their bistrifluoroacetate salts 11 and 12, respectively.

Electron Spin Resonance Studies of Electron Capture Processes. Part 7. ?* (3-Electron Covalent Bond) Radical Anions of Halogenoimidazoles

Exposure of dilute solutions of 4-bromo- and 4-iodo-2-methylimidazole, 5-bromo- and 5-iodo-1,2-dimethylimidazole, and 4,5-dibromo- and 4,5-diiodo-1,2-dimethylimidazole in methanol (CD3OD) or methyltetrahydrofuran (MeTHF) to 60Co γ-rays at 77 K resulted in electron addition to yield not the expected ?* radical anions but ?* radical anions.In these radical anions the SOMO is primarly the C-Hal ?* molecular orbital with little delocalisation into the imidazole ring, i.e. a 3-electron ? bond.On slowly increasing the temperature of the MeTHF solutions of the bromoimidazoles the hyperfine features for the ?* radical anions were lost but with no clear concomitant growth of features assignable to 4- or 5-imidazolyl radicals.However, for the iodoimidazoles (2), (4), and (6) in CD3OD a new species was observed on annealing.The same species was observed for all three iodo compounds and is assigned to iodine atoms weakly bonded to CD3OD molecules O(D)CD3>.The results are discussed in the light of the ?* and/or ?* species obtained from electron capture by other aromatic halides and other substituted imidazoles.

2(1H)-Quinolinones with Cardiac Stimulant Activity. 3. Synthesis and Biological Properties of 6-Imidazol-1-yl Derivatives

A series of 6-imidazol-1-yl-8-methyl-2(1H)-quinolinones was synthesized and evaluated for cardiac stimulant activity in dogs.The majority of compounds were prepared from an appropriate 6-imidazol-1-yl-2(1H)-quinolinone precursor or by sulfuric acid cataly

6-heteroaryl quinolone inotropic agents

A series of novel heterocyclic-substituted 2-(1H)-quinolone compounds have been prepared, including the 3,4-dihydro derivatives thereof, wherein the heterocyclic ring moiety is a pyrrolyl, imidazolyl, pyrazolyl, triazolyl or tetrazolyl group attached by a nitrogen atom of said group to the 5-, 6-, 7- or 8-positions of the quinolone ring. These particular compounds are useful in therapy as highly potent inotropic agents and therefore, are of value in the treatment of various cardiac conditions. Preferred member compounds include 6-(2,4-dimethylimidazol-1-yl)-8-methyl-2-(1H)-quinolone, 6-(2,4-dimethyl-5-nitroimadazol-1-yl)-8-methyl-2-(1H)-quinolone, 8-methyl-6-(tetrazol-1-yl)-2-(1H)-quinolone, 8-methyl-6-(1,2,4-triazol-4-yl)-2-(1H)-quinolone, and 6-(4-cyano-2-methylimidazol-1-yl)-8-methyl-2-(1H)-quinolone, respectively. Methods for preparing these compounds from known starting materials are provided.

Methyl substituted imidazol-1-yl quinolones

A series of novel heterocyclic-substituted 2-(1H)-quinolone compounds have been prepared wherein the heterocyclic ring moiety is a substituted pyrrolyl, imidazolyl, pyrazolyl, triazolyl or tetrazolyl group attached by a nitrogen atom of said group to the